Comparison · NCT02394795-a6aa2c3d
Group P; mFOLFOX6 + Panitumumab Combination Therapy vs Group B; mFOLFOX6 + Bevacizumab Combination Therapy: Number of Participants With Treatment-emergent Adverse Events (TEAE)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group P; mFOLFOX6 + Panitumumab Combination Therapy vs Group B; mFOLFOX6 + Bevacizumab Combination Therapy: Number of Participants With Treatment-emergent Adverse Events (TEAE). Trial comparisons, record NCT02394795-a6aa2c3d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02394795-a6aa2c3d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.995 | 0.982 | 0.999 | wilson | |
| Risk in group 2 | 0.978 | 0.959 | 0.988 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0172 | 0.000556 | 0.0369 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.02 | 1 | 1.03 | log | |
| Odds ratio, group 1 over group 2 | 4.55 | 0.976 | 21.2 | log | |
| Number needed to treat, for one more participant with the outcome on Group P; mFOLFOX6 + Panitumumab Combination Therapy than on Group B; mFOLFOX6 + Bevacizumab Combination Therapy | 58.3 | 27.1 | 1,800 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group P; mFOLFOX6 + Panitumumab Combination Therapy | OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 panitumumab: 6 mg/kg mFOLFOX6 + panitumumab combination therapy, once every two weeks. | 402 | 404 | OG000 |
| Group 2 | Group B; mFOLFOX6 + Bevacizumab Combination Therapy | OXA: 85 mg/m2/day 1 l-LV: 200 mg/m2/day 1 5-FU iv: 400 mg/m2/day 1 5-FU civ: 2400 mg/m2/day 1-3 bevacizumab: 5 mg/kg/ mFOLFOX6 + bevacizumab combination therapy, once every two weeks. | 398 | 407 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Treatment-emergent Adverse Events (TEAE)
- Description
Adverse event (AE) was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which did not necessarily have a causal relationship with this treatment. A TEAE was defined as an adverse event with an onset that occurred in the treatment period after receiving the protocol treatment.
- Time frame
- Up to approximately 60 months
- Population
- Safety analysis set (SAS): all patients who initiated the protocol treatment.
Source ClinicalTrials.gov
Trial
- Title
- Panitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
- NCT number
- NCT02394795
- Phases
- PHASE3
- Conditions
- Colorectal Cancer
- Interventions
- oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab, oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab
- Lead sponsor
- Takeda
- Results first posted
- 2023-11-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02394795?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02394795-a6aa2c3d